Introduction The analysis of cell-free DNA or liquid biopsy is emerging as a noninvasive clinical tool to aid in achieving accurate diagnoses. It is also a valuable research tool to determine biomarkers of disease, identify drug targets, and ascertain the factors responsible for drug resistance. Circulating tumor DNA refers to cell-free DNA that are fragments […]
Introduction Various types of home diagnostic testing or screening have placed more power and control of individual health information and care in the hands of consumers. We are well familiar with and may have used (or know someone who has) blood pressure kits, glucose measurement kits, and home pregnancy tests. Due to the next-generation sequencing […]
Introduction The need for accurate and rapid identification of infectious agents in individual illness and global health threats cannot be overstated. Limitations in the timeliness and accuracy of pathogen identification have devastating public health consequences. The current methods that are routinely used often provide data in a time span that does not allow the most […]
Introduction and Brief overview of NGS An important technological advance in the practice of diagnostic and clinical medicine is next-generation sequencing (NGS). This technology is rapidly transforming clinical practice by providing a means to obtain both diagnostic and prognostic data with the same data. This transformation is made possible because of the cost-effective and rapid […]
Psomagen, Inc. (previously Macrogen Corp.), established in 2004, offers “total genomic solutions” for both clinical and research purposes, mainly focusing on end-to-end sequencing services. The company will expand its services to include personal DNA tests.
inquiry@nullpsomagen.com
(301) 251-1007
ROCKVILLE, MARYLAND (HQ)
CLIA: 21D2062464 | CAP: 8742212
BROOKLYN, NEW YORK
CAMBRIDGE, MASSACHUSETTS
STERLING, VIRGINIA
CLIA: 49D2172599
KOSDAQ: PSOMAGEN INC (950200)